2-[(4E,6Z)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: 2-[(4E,6Z)-7-cyano-8,16-dihydroxy-9,11,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca-4,6-dien-2-yl]cyclopentane-1-carboxylic acid
• 化学式: C₂₈H₄₃NO₆
• 分子量: 489.6
• InChiKey: OJCKRNPLOZHAOU-SDBBXGPLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• HETEROCYCLIC COMPOUNDS INHIBITING ANGIOGENESIS
  申请人：Gyogyszerkutato Intézet KFT

  公开号：EP1206462B1

  公开（公告）日：2003-05-28
• US6815465B1
  申请人：——

  公开号：US6815465B1

  公开（公告）日：2004-11-09
• [EN] ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] COMPOSÉS ANTI-INFLAMMATOIRES
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2009141786A2

  公开（公告）日：2009-11-26

  The present invention provides use of borrelidin, an isomer, or pharmaceutically acceptable salt thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising borrelidin, an isomer, or pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of borrelidin, an isomer, or pharmaceutically acceptable salt thereof to a subject in need thereof. The said inflammatory disorder may be mediated by elevated levels of one or more inflammatory cytokines selected from Tumor Necrosis Factor-alpha (TNF-α) and interleukins (IL-1 β, IL-6, IL-8) or increased expression of one or more cell adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1 ), vascular-cell adhesion molecule 1 (VCAM-1 ) and E-Selectin or a combination thereof.